Scoring functions used in structure-based drug design are often inefficient in reliably placing near-native geometries on the first scoring rank. Furthermore, there is no means to incorporate protein-specific information which additionally captures interaction details of different experimentally observed binding modes with the target protein under consideration.
Scoring functions used in structure-based drug design are often inefficient in reliably placing near-native geometries on the first scoring rank. Furthermore, there is no means to incorporate protein-specific information which additionally captures interaction details of different experimentally observed binding modes with the target protein under consideration.
Here, we present a vector-based extension of the DrugScore CSD formalism [1] , called DrugScore Fingerprints (DrugScore FP ), to rescore docking results. The original DrugScore of a docked inhibitor is partitioned into peratom scores resulting in a 1D vector. Simple distance metrics allow the determination of similarities between fingerprints of docked compounds and reference fingerprints derived from crystal structures. Furthermore, DrugScore FP allows the generation of family-based fingerprint profiles similarly implemented in SIFT [2, 3] [4]. Therefore, a weighted consensus vector is derived from a given set of co-crystallized inhibitors with the target protein. Thus, DrugScore FP binding profiles capture similarities and dissimilarities with respect to drug targets for which a large amount of structural data is available.
We have applied DrugScore FP to handle the following tasks in structure-based drug design:
The recognition of near-native docking-poses was improved compared to DrugScore CSD and SIFT using the Wang dataset [5] . DrugScore FP places geometries <0.5Å rmsd on the first scoring rank in 94% of the cases. This indicates an improvement compared to the original DrugScore CSD of 6% and SIFT of 18%. Furthermore, cross-validation studies on different consensus fingerprints were performed with respect to a trypsin dataset consisting of 61 co-crystallized ligand structures. In a leave-one-out experiment, DrugScore FP showed better recognition rates of crystal structures than docked compounds in 75% of the cases. As a final step, GOLD was used to dock 1800 compounds from the National Cancer Institute Diversity Set (NCI; http://www.nci.nih.gov) into trypsin and HIV-1 protease. DrugScore FP shows superior ROC-AUCs of up to 99% compared to GOLD-Score (72%) and DrugScore CSD (85%), using a fingerprint profile constructed from 61 and 22 co-crystallized ligands as query for the trypsin and the HIV-1 protease screen, respectively.
Finally, the results prove that DrugScore FP can be used as a powerful filter, identifying similar binding profiles. It could also be shown that DrugScore FP is stable with respect to cross-validations. It reliably discriminates nearnative poses from widely spread decoys and retrieves active compounds diluted in a large dataset almost perfectly.
